Plum modulates Myoglianin and regulates synaptic function in D. melanogaster.

Alterations in the neuromuscular system underlie several neuromuscular diseases and play critical roles in the development of sarcopenia, the age-related loss of muscle mass and function. Mammalian Myostatin (MST) and GDF11, members of the TGF-ß superfamily of growth factors, are powerful regulators of muscle size in both model organisms and humans. Myoglianin (MYO), the Drosophila homologue of MST and GDF11, is a strong inhibitor of synaptic function and structure at the neuromuscular junction in flies. Here, we identified Plum, a transmembrane cell surface protein, as a modulator of MYO function in the larval neuromuscular system. Reduction of Plum in the larval body-wall muscles abolishes the previously demonstrated positive effect of attenuated MYO signalling on both muscle size and neuromuscular junction structure and function. In addition, downregulation of Plum on its own results in decreased synaptic strength and body weight, classifying Plum as a (novel) regulator of neuromuscular function and body (muscle) size. These findings offer new insights into possible regulatory mechanisms behind ageing- and disease-related neuromuscular dysfunctions in humans and identify potential targets for therapeutic interventions.

Oral administration of green plant-derived chemicals and antioxidants alleviates stress-induced cellular oxidative challenge.

BACKGROUND: This study examined the efficacy of the combination antioxidant, Formula 42 (F42), on cellular stress indicators in animal and human models of stress-induced oxidative stress. METHODS: A sub-chronic psychological stress model in rodents was used to induce stress and oxidative stress indicators over a 10-day period during which animals received oral doses of F42 or water. Following treatment, body weight, plasma stress hormone corticosterone, and oxidative capacity were evaluated. In healthy human subjects, a randomized double-blind crossover study was used to examine the antioxidant effect of F42 or placebo in an exercise-induced oxidative stress model. Erythrocyte and plasma oxidative status was evaluated using the fluorescent activation of 2',7'-dichlorofluorescin (DCF) as an indicator. RESULTS: Oral administration of F42 reduced the corticosterone response to acute stress compared to vehicle but did not differ at the conclusion of the 10-day study. However, F42 administration did reduce stress-induced growth restriction and alleviate DCF activation in circulating erythrocytes by approximately 10% following 10 days of stress exposure. Oral administration of F42 also significantly reduced DCF activation by approximately 10% in healthy human subjects undergoing exercise-induced oxidative stress. CONCLUSIONS: Oral administration of F42 in rodents produces transient reductions in stress hormones and reduces stress indicators following sub-chronic psychological stress exposure. In humans, F42 acts as an early and potent antioxidant capable of scavenging free radicals within 30 min of ingestion.